These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37688683)

  • 1. Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A
    Ma Q; Li M; Xu G
    Clin Exp Med; 2023 Dec; 23(8):5337-5343. PubMed ID: 37688683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
    Yan P; Fang X; Ke B
    Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
    Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
    PeerJ; 2022; 10():e14193. PubMed ID: 36248712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.
    Chen P; Mao M; Wang C; Zhang X; Zhao X; Gao Y; Luo Y; Zhou Y
    Front Endocrinol (Lausanne); 2023; 14():1044782. PubMed ID: 36875477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels.
    Xue C; Wang J; Pan J; Liang C; Zhou C; Wu J; Song S; Cui L; Zhang L; Liu Y; Dai B
    BMC Nephrol; 2023 Sep; 24(1):280. PubMed ID: 37740193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
    Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
    Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
    Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
    Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
    Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
    Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.
    Wang B; Zhu Z; Huang F; Huang H; Tu L; Wang Y; Zheng L; Zhou J; Wei X
    BMC Nephrol; 2022 Sep; 23(1):306. PubMed ID: 36068486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
    Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
    Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
    van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
    J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the efficacy of different treatments for idiopathic membranous nephropathy: a retrospectively real-world study.
    Sun M; Huang J; Dong J; Li Z; Li C; Zhang S; Chen B
    Curr Med Res Opin; 2023 May; 39(5):761-769. PubMed ID: 36938631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
    Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
    Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A novel approach to rapid induction of remission in primary membranous nephropathy].
    Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
    Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of ultra-low dose rituximab and low dose tacrolimus versus tacrolimus alone in the treatment of non-responsive idiopathic membranous nephropathy: a Chinese retrospective cohort study.
    Zhu F; Chu X; Guo Y; Li Y; Cao C; Wu J; Xu H; Deng X; Li J; Liu X; Yao Y; Zeng R
    Am J Transl Res; 2021; 13(7):7622-7631. PubMed ID: 34377239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience.
    Wang YW; Wang XH; Wang HX; Yu RH
    World J Clin Cases; 2023 Jan; 11(3):566-575. PubMed ID: 36793628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.